Drug Channels

MARCH 15, 2022

Licenses for our DCI reports are regularly purchased by nearly every company involved in the drug channel: pharmaceutical manufacturers, wholesalers, pharmacists, pharmacy owners, hospitals, buyers, benefit managers, managed care executives, policy analysts, investors, consultants, and more.

Pharmacy 98

Pharmacy Specialty Pharmacies Licensing Licensing 98

Drug Target Review

APRIL 14, 2025

By preventing infections before they occur, these drugs reduce the need for hospital treatments, including the costly intensive care unit (ICU) care that can burden healthcare systems. As Finrow reflects, “If we can keep people out of hospital ICUs, thats even more value delivered.

Therapies 52

Therapies Marketing Drug Development Treatment 52

The Pharma Data

DECEMBER 14, 2020

15, 2020 (GLOBE NEWSWIRE) — Burning Rock Biotech Limited (NASDAQ: BNR, the “Company” or “Burning Rock”) today announced that it entered into an exclusive licensing agreement with Oncocyte Corporation (NYSE American: OCX) to bring DetermaRx , a risk stratification test for early stage lung cancer patients, to China.

Licensing 52

Licensing Licensing Pharmaceutical Companies Treatment 52

The Pharma Data

OCTOBER 30, 2020

(NASDAQ: REGN) received today a recommendation from the independent data monitoring committee (IDMC) for the REGN-COV2 antibody cocktail treatment trials for COVID-19 that the current hospitalized patient trial be modified. About the REGN-COV2 Trial in Hospitalized Patients. Cohort 1A: patients not requiring oxygen.

Hospitals 52

Hospitals Virus Production Clinical Trials 52

The Pharma Data

SEPTEMBER 30, 2020

image caption Independent hospital group Circle Health Group said it was taking the issues “incredibly seriously” Claims a surgeon kept the bones of more than 5,000 patients he operated on have led to a police inquiry. image copyright Google. Circle Health Group said the “historic issues.

Hospitals 52

Hospitals Licensing Licensing Regulations 52

Advarra

APRIL 30, 2024

A cross-check ensures curriculum vitae (CVs), and medical licenses (if appropriate) are on file and current. For example, most hospital radiology technicians are trained to perform scans for the hospital and/or PI for clinical trials based on the information in the test requisitions. based sites. Sites outside of the U.S.

Licensing 52

Licensing Licensing Pharmacy FDA 52

The Pharma Data

OCTOBER 6, 2021

It is also licensed under the brand name Efluelda ® in Europe where it is indicated for adults aged 60 and older. It is also licensed under the brand name Efluelda® in Europe where it is indicated for adults aged 60 and older. About Sanofi. Sanofi is dedicated to supporting people through their health challenges.

Vaccine 52

Vaccine Licensing Licensing Immune Response 52

The Pharma Data

DECEMBER 14, 2020

Harbour BioMed (HBM) announced with Utrecht University on Monday that they have licensed their fully human SARS-CoV-2 neutralizing antibody, 47D11, and its program to AbbVie. Specifically, it is being examined in adults who are hospitalized with COVID-19. Kate Krav-Rude/Shutterstock. before expanding it into Europe.

Licensing 52

Licensing Licensing Pharmacokinetics Clinical Trials 52

The Pharma Data

MARCH 8, 2021

Phase 2a study enrolled 202 non-hospitalized adults who had signs or symptoms of COVID-19 within 7 days and confirmed active SARS-CoV-2 infection. Since licensed by Ridgeback all funds used for the development of EIDD-2801 by Ridgeback have been provided by Wayne and Wendy Holman and Merck. This press release features multimedia.

Trials 69

Trials Virus RNA Research Laboratories 69

The Pharma Data

NOVEMBER 18, 2020

Department of Internal Medicine, Tri-Service General Hospital, Taipei, Taiwan. Department of Hematology and Oncology, Taipei Medical University Hospital, Taipei, Taiwan. current affiliation: Department of Hematology and Oncology, Taipei Tzu Chi Hospital, Taipei, Taiwan. Presenter: Ching-Liang Ho MD, et.al. About OBI Pharma.

Vaccine 52

Vaccine Small Molecule Immune Response Hospitals 52

The Pharma Data

JANUARY 14, 2021

While the new guidelines pertain to physicians who treat no more than 30 patients with buprenorphine for opioid use disorder at any one time, ACEP appreciates that the Department recognized the unique nature of emergency medicine and decided not to apply this limitation to hospital-based physicians, including emergency physicians.

Treatment 52

Treatment Licensing Licensing Hospitals 52

The Pharma Data

JULY 12, 2021

The Phase 3 portion of the global MOVe-OUT trial studying molnupiravir in non-hospitalized adult patients with laboratory-confirmed COVID-19 and at least one risk factor associated with poor disease outcomes is underway. in collaboration with Ridgeback Biotherapeutics. About Ridgeback Biotherapeutics.

Clinical Trials 52

Clinical Trials Laboratories Research Laboratories RNA 52

Fierce BioTech

FEBRUARY 6, 2024

To drive better results hospital executives, care teams, and clinical innovators alike must re-imagine how, when, and where care is being delivered. Saurabh Chandra John Bruinsma Duration 60 minutes Major staffing shortages, rising costs, and strained bed capacity are punctuating the post-covid reality – the old way isn’t working!

Nurses 52

Nurses Licensing Licensing Hospitals 52

The Pharma Data

OCTOBER 26, 2020

AR-711 is currently being developed as an inhaled, self-administered treatment for non-hospitalized patients suffering from mild to moderate COVID-19. aeruginosa hospital acquired pneumonia cases worldwide. AR-711 is an in-licensed mAb that is directed against the receptor binding domain of the SARS-Cov 2 virus.

Pharmaceuticals 52

Pharmaceuticals Virus Hospitals Clinical Trials 52

The Pharma Data

SEPTEMBER 2, 2021

Data suggesting that the treatment of severe asthma exacerbations may have a negative environmental impact due to ambulance trips, emergency room visits and hospitalizations: the carbon footprint of a single severe asthma exacerbation could be equivalent to the use of a dry powder inhaler (Breezhaler ® ) for approximately 74 years 7.

Licensing 52

Licensing Licensing Treatment Therapies 52

The Pharma Data

JANUARY 13, 2021

Fast Track designation is well-timed, as we anticipate starting our Phase 2 clinical trial in hospitalized COVID-19 patients this month, and should help bring Brilacidin to patients faster in these dire times.”. Brilacidin for UP/UPS was licensed to Alfasigma S.p.A.

Clinical Trials 52

Clinical Trials Trials Treatment Pharmaceuticals 52

The Pharma Data

AUGUST 16, 2021

Vaccination is our most effective means of preventing COVID-19 infection – especially severe disease and hospitalization – and its profound impact on protecting lives is indisputable. The Pfizer-BioNTech COVID-19 Vaccine has not been approved or licensed by the U.S. This press release features multimedia. In the U.S.,

Vaccine 52

Vaccine FDA Virus Immune Response 52

The Pharma Data

NOVEMBER 29, 2020

Y-mAbs Therapeutics has a target action date of November 30 for its Biologics License Application (BLA) for Danyelza (naxitamab) for patients with relapsed/refractory high-risk neuroblastoma. The drug was developed by researchers at Memorial Sloan Kettering Cancer Center and exclusively licensed to Y-mAbs.

FDA 52

FDA Licensing Licensing Pharmaceuticals 52

The Pharma Data

DECEMBER 30, 2020

Their experienced medical field staff of 1,500 EMTs, paramedics and licensed practical nurses work under the guidance of MD1 Medical Care PC to fill the gap between a visit to the doctor’s office and a traditional telemedicine call. . View original content to download multimedia: [link].

Nurses 52

Nurses Hospitals Virus Licensing 52

FDA Law Blog: Biosimilars

JULY 5, 2023

Under section 503B, drugs compounded by an FDA-registered outsourcing facility under the supervision of a licensed pharmacist can qualify for exemptions from FDA approval, labeling with adequate directions for use, and certain drug supply chain security requirements, subject to specific conditions. Draft Guidance III.B.2(e)

FDA 52

FDA FDA Approval Licensing Licensing 52

The Pharma Data

NOVEMBER 25, 2020

With management expertise in hospitality and finance, the Burkhan World Group of Companies, based in Washington D.C. , . “Our new partner, Vivera Pharmaceuticals, is the ideal strategic partner for our vision to make a difference in peoples’ lives.” About Vivera Pharmaceuticals, Inc.

Pharmaceuticals 40

Pharmaceuticals Hospitals Pharmaceutical Companies Licensing 40

The Pharma Data

OCTOBER 15, 2020

The naxitamab data was presented by Dr. Jaume Mora from SJD Barcelona Children’s Hospital, and the omburtamab data was presented by Dr. Kim Kramer from Memorial Sloan Kettering Cancer Center (“MSK”). Researchers at MSK developed naxitamab and omburtamab, which are exclusively licensed by MSK to Y-mAbs. About Y-mAbs.

Licensing 52

Licensing Licensing Production Treatment 52

The Pharma Data

OCTOBER 18, 2020

Berk completed his internship, residency, and fellowship in internal medicine, hematology, and medical oncology at the Weill Cornell Medical College and New York Presbyterian Hospital, where he also served as a faculty member. The company’s pipeline was licensed from the Spanish National Cancer Research Centre (CNIO).

Small Molecule 40

Small Molecule Clinical Development Clinical Trials Licensing 40

The Pharma Data

AUGUST 20, 2020

What information has been released about how kits were assessed shows most were tested on small numbers of patients only – just a few dozen, all of whom had been admitted to hospital. “For drug licensing the onus is on the companies to go through clinical trials.

Clinical Trials 52

Clinical Trials Regulations Doctors Government 52

The Pharma Data

NOVEMBER 5, 2020

Humanigen announced positive interim Phase III data of lenzilumab in hospitalized COVID-19 patients. Targeting 402 events improves the probability of success, maintains the power of the study at 90%, and further supports our plans for Emergency Use Authorization (EUA) and Biologics License Application (BLA) submission.

Clinical Trials 40

Clinical Trials Trials Hospitals Pharmaceutical Companies 40

The Pharma Data

APRIL 4, 2022

The high rate of unvaccinated people will continue to put a strain on hospitals and healthcare systems around the world, furthering the need for effective treatments for patients hospitalised with COVID-19,” said Levi Garraway, M.D., today announced that the U.S. A decision on U.S. FDA approval is expected in the second half of this year.

Treatment 52

Treatment FDA Approval Clinical Trials FDA 52

Drug Target Review

FEBRUARY 1, 2024

We were able to license a molecule from a multi-national pharmaceutical company. We have been hard at work for two-and-a-half years on developing a precision treatment for GRIN-related disorders, a genetically defined developmental epileptic encephalopathy. It’s a great example of how our model works.

Therapies 104

Therapies Drug Development Disease Clinical Development 104

The Pharma Data

MAY 5, 2022

“Today, 30-60% of patients with GvHD do not respond to first-line steroid treatment, underscoring the need for new approaches to ensure long-term treatment goals are met,” said Dr. Robert Zeiser, University Hospital Freiburg, Department of Haematology, Oncology and Stem Cell Transplantation, Freiburg, Germany.

Treatment 52

Treatment Disease Therapies Clinical Trials 52

The Pharma Data

JUNE 26, 2021

In line with our global leadership and our 7 0-year history of pro tecting people with influenza v accine s , w e will always focus on developing product s that demonstrate protection beyond flu , as we believe it is critical to demonstrate protecting patients from hospitalizations due to cardiovascular events and pneumonia.

Clinical Trials 52

Clinical Trials Vaccine Trials Immune Response 52

The Pharma Data

MARCH 2, 2021

The Company plans to file for a Biologics License Application (BLA) with the FDA later in 2021. The Janssen COVID-19 vaccine has not been approved or licensed by the U.S. If you experience a severe allergic reaction, call 9-1-1, or go to the nearest hospital. WHAT SHOULD I DO ABOUT SIDE EFFECTS? Source link:[link].

Vaccine 52

Vaccine Clinical Trials FDA Licensing 52

The Pharma Data

NOVEMBER 19, 2020

. ° Magnis BR, Burning Rock’s fully automated NGS library preparation system, is a key component of Burning Rock’s strategy of empowering hospitals to run NGS tests in-house with minimized lab space and staff requirement. Revenue generated from in-hospital business was RMB31.7 In-hospital Channel: .

Hospitals 52

Hospitals Laboratories Marketing Research 52

The Pharma Data

MARCH 4, 2021

Food and Drug Administration (FDA) has accepted for review the supplemental Biologics License Application (sBLA) for Dupixent ® (dupilumab) as an add-on treatment for children aged 6 to 11 years with uncontrolled moderate-to-severe asthma.

FDA 52

FDA Disease Treatment FDA Approval 52

The Pharma Data

MARCH 27, 2022

OLUMIANT, a once-daily, oral JAK inhibitor was discovered by Incyte and licensed to Lilly. Marketing authorization for the treatment of hospitalized patients with COVID-19 has been granted for OLUMIANT in multiple countries. ” About OLUMIANT®. It is approved in the U.S. It is approved in the U.S.

Licensing 40

Licensing Licensing Disease FDA Approval 40

The Pharma Data

SEPTEMBER 8, 2020

Fourteen newly licensed medicines have been accepted for use on NHS Scotland by the Scottish Medicines Consortium (SMC), bringing a raft of new treatment options for conditions including epilepsy, depression and cancer.

Treatment 52

Treatment Clinical Trials Licensing Licensing 52

The Pharma Data

JANUARY 18, 2021

At the same time, we continue to prepare for the filing of the Biologics License Application with the U.S. million in 2020 despite a very limited access of patients to hospitals due to the COVID-19 crisis. “We Cash position and financing runway. million in the fourth quarter of 2020, and to a total of €5.6

Treatment 40

Treatment Therapies Clinical Trials Marketing 40

The Pharma Data

OCTOBER 27, 2020

The study’s objectives are to evaluate the efficacy and safety of NexoBrid compared with the standard-of-care in hospitalized children with severe thermal burns of 1 percent to 30 percent Total Body Surface Area (TBSA). patients during the review of the NexoBrid Biologics License Application (BLA).

Clinical Trials 40

Clinical Trials Licensing Licensing FDA 40

The Pharma Data

OCTOBER 19, 2020

Pneumococcal serotypes not in the currently licensed conjugate vaccine, such as 22F and 33F, are among the most common serotypes causing invasive pneumococcal disease in parts of the world, including the U.S., among adults 65 years of age or older. About Pneumococcal Disease.

Vaccine 52

Vaccine Immune Response Disease Clinical Trials 52